Body Cavity- Based Lymphoma in a Country with Low Human Immunodeficiency Virus Prevalence: A Series of 17 Cases from the Consortium for Improving Survival of Lymphoma
- 문서 유형
- 연구출판물 · 학술지 논문
- 등재
- KCISCIEScopus
- 저널 순위
- JCR Q2Scopus Q2
- 저널
- Cancer Research and Treatment51(4) · pp.1302 · 2019
- 피인용
- Web of Science 8Scopus 9KCI 0
- FWCI (Scopus)
- 0.37
- JCR IF
- JCR 2018 3.363
- ISSN
- 1598-2998
저자
- Shin, Junghoon제1저자Department of Internal Medicine, Seoul National University Hospital, Seoul
- Ko, Young HyehDepartment of Pathology, Samsung Medical Center, Seoul
- Oh, Sung YonDepartment of Internal Medicine, Dong-A University College of Medicine, Busan
- Yoon, Dok HyunDepartment of Oncology, Asan Medical Center, Seoul
- Lee, Jeong-OkDepartment of Internal Medicine, Seoul National University Bundang Hospital, Seongnam
- Kim, Jin SeokDepartment of Internal Medicine, Yonsei University College of Medicine, Seoul
- Park, YongDepartment of Internal Medicine, Korea University Anam Hospital, Seoul
- 신호진Department of Internal Medicine, Pusan National University Hospital, Busan
- Kim, Seok JinDepartment of Medicine, Samsung Medical Center, Seoul
- Won, Jong HoDepartment of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
- Yoon, Sung-SooDepartment of Internal Medicine, Soonchunhyang University Seoul Hospital, Seoul, Korea
- Kim, Won SeogDepartment of Medicine, Samsung Medical Center, Seoul
- Koh, Youngil교신저자Department of Internal Medicine, Seoul National University Hospital, Seoul
초록
Purpose Primary effusion lymphoma (PEL) is a type of body cavity-based lymphoma (BCBL). Most patients with PEL are severely immunocompromised and seropositive for human immunodeficiency virus (HIV). We investigated the distinctive clinicopathologic characteristics of BCBL in a country with low HIV burden. Materials and Methods We retrospectively collected data on the clinicopathologic characteristics, treatments, and outcomes of 17 consecutive patients with BCBL at nine institutions in Korea. Results Latency-associated nuclear antigen 1 (LANAI.) immunostaining indicated that six patients had PEL, six patients had human herpesvirus 8 (HHV8)-unrelated BCBL, and five patients had HHV8-unknown BCBL. The patients with PEL exhibited no evidence of immunodeficiency except for one who was HIV positive. One (20%) and four (80%) patients with PEL and six (100%) and zero (0%) patients with HHV8-unrelated BCBL were positive for CD20 and CD30 expression, respectively. The two patients with PEL (one HIV-positive and one HIV-negative patient) with the lowest proliferation activity as assessed by the Ki-67 labeling index survived for > 1 and > 4 years without chemotherapy, respectively, in contrast to the PEL cases in the literature, which mostly showed a high proliferation index and poor survival. Conclusion PEL mostly occurred in ostensibly immunocompetent individuals and had a favorable outcome in Korea. A watchful waiting approach may be applicable for managing HIV-seronegative patients with PEL with a low Ki-67 labeling index. A possible trend was detected among LANA1, CD20, and CD30 expression in BCBL.
키워드
Body cavity-based lymphomaPrimary effusion lymphomaHuman herpesvirus 8Human immunodeficiency virusImmunophenotypePRIMARY-EFFUSION LYMPHOMAHIV-INFECTED PATIENTSKAPOSIS-SARCOMABRENTUXIMAB VEDOTINPATIENTENTITYREMISSION
식별자
- Scopus EID
- 2-s2.0-85076757707
- WoS UID
- 000489753500006
- KCI
- ART002513357



로그인
연구물 목록으로